An observational study in Chagas Disease, sponsored by Hospital de Niños R. Gutierrez de Buenos Aires. Status unknown at 1 site in Argentina. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2023-03-01.
Sponsored by Hospital de Niños R. Gutierrez de Buenos Aires · Observational
Chagas disease is caused by parasite Trypanosoma Cruzi. In Argentina, there is an estimated of 1.600.000 infected people. Due to migration phenomenon, most cases live in urban areas without vectorial transmission.
Pharmacological treatment is given to prevent development of cardiac and gastrointestinal sequelae. There are two available drugs for this disease; Nifurtimox and Benznidazole. They both has proven efficacy for acute face treatment, with different security profiles. There are not enough adequate studies comparing both drugs made in a large number of subjects. Investigators will study 900 patients treated with both drugs and compare security and efficacy in a retrospective cohort.
All pediatric patients with criteria to receive treatment (Chagas infection confirmed) that received treatment and completed follow-up at Parasitology and Chagas department of Children's Hospital Ricardo Gutierrez, Argentina.
Exclusion Criteria:
Patients treated with Nifurtimox from 1984 to 2017
Other: Clinical Manifestations · Diagnostic Test: Serologic response · Diagnostic Test: Direct method · Behavioral: Adverse events
Patients treated with Benznidazole from 1984 to 2017
Other: Clinical Manifestations · Diagnostic Test: Serologic response · Diagnostic Test: Direct method · Behavioral: Adverse events
Clinical manifestations in patients treated with Nifurtimox and Benznidazole
Serologic response in patients treated with Nifurtimox and Benznidazole
Direct method tests in patients treated with Nifurtimox and Benznidazole
Adverse events in patients treated with Nifurtimox and Benznidazole
Nifurtimox versus Benznidazole serologic, parasitemia and clinical response for treatment in patients
To compare Nifurtimox versus Benznidazole treatment efficacy, by measuring serologic response, parasitemia and clinical manifestations in infected patients
Time frame: Patients treated from 1984 to 2017
Nifurtimox versus Benznidazole security and tolerance
To compare Nifurtimox versus Benznidazole security profiles, by measuring adverse events in infected patients and comparing both groups (number of adverse reactions, type and severity of reactions)
Time frame: Patients treated from 1984 to 2017
To compare Chagas disease characteristics associated with treatment
To describe source of infection, age of acquisition of parasite, diagnosis time frame and clinical manifestations that may be associated with treatment response and compare both groups
Time frame: Patients treated from 1984 to 2017
This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital de Niños R. Gutierrez de Buenos Aires